Adaptation of the COVASIM model to incorporate non-pharmaceutical interventions: Application to the Dominican Republic during the second wave of COVID-19
Author:
Solares-Hernández Pedro A.12, Garibo-i-Orts Òscar23, Alberto Conejero J.2, Manzano Fernando A.1
Affiliation:
1. 1 Universidad APEC. Santo Domingo , Dominican Republic . 2. 2 Instituto Universitario de Matemática Pura y Aplicada. Universitat Politècnica de València , Spain . 3. 3 GRID - Grupo de Investigación en Ciencia de Datos . Valencian International University - VIU , Spain .
Abstract
Abstract
We adapt the Covasim agent-based model for predicting new COVID-19 cases by tuning the transmissibility rate with information on the impact of the most common non-pharmaceutical interventions (NPIs) obtained through machine learning models. Such impact has been estimated thanks to the information on applying pools of NPIs worldwide from the Oxford COVID-19 Government Response Tracker.
This approach permits the simulation of a whole country or a smaller region, providing information about asymptomatic, recovery, severe, and critical new cases and enabling governments and authorities to set NPIs plans to cope with the pandemic.
Publisher
Walter de Gruyter GmbH
Subject
Applied Mathematics,Engineering (miscellaneous),Modeling and Simulation,General Computer Science
Reference49 articles.
1. Alimohamadi, Y., Sepandi, M., Taghdir, M., & Hosamirudsari, H. (2020). Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J. Prev. Med. Hyg., 61(3), E304. 2. Sáez, C., Romero, N., Conejero, J. A., & García-Gómez, J. M. (2021). Potential limitations in COVID-19 machine learning due to data source variability: A case study in the ncov2019 dataset. J. Am. Med. Inform. Assoc., 28(2), 360–364. 3. Zhou, L., Romero-García, N., Martínez-Miranda, J., Conejero, J. A., et al. (2022). Subphenotyping of Mexican patients with COVID-19 at preadmission to anticipate severity stratification: age-sex unbiased meta-clustering technique. JMIR Public Health Surveill., 8(3), e30032. 4. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., et al. (2020). Remdesivir for the treatment of COVID-19 preliminary report. N. Engl. J. Med., 383(19), 1813–1836. 5. Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020). COVID-19: Immunology and treatment options. Clin. Immunol., 215, 108448.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|